- Year selection
- 2022
- 2033
-
2026-02-03
VOLUNTARY ANNOUNCEMENT M701 RECEIVES IND APPROVAL FROM FDA
-
2026-01-26
INSIDE INFORMATION ISSUANCE OF FILING NOTICE BY THE CSRC IN RESPECT OF THE H SHARE FULL CIRCULATION BY THE COMPANY
-
2026-01-23
DISCLOSEABLE TRANSACTION TRANSFER OF LAND USE RIGHT AND BUILDING
-
2026-01-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
-
2025-12-31
CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR
-
2025-12-24
VOLUNTARY ANNOUNCEMENT - Y225 "EMICIZUMAB INJECTION" RECEIVES IND APPROVAL FROM NMPA
-
2025-12-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
-
2025-12-02
VOLUNTARY ANNOUNCEMENT - Phase II Data of M701 for Malignant Ascites Published in ExperimentalHematology & Oncology
-
2025-11-06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
-
2025-10-19
VOLUNTARY ANNOUNCEMENT - PHASE II STUDY INTERIM DATA OF M701 FOR MALIGNANT PLEURAL EFFUSION PRESENTED AT THE ESMO CONGRESS 2025
E-Mail：info@yzybio.com
Address：Biolake, C2-1, No. 666 High-tech Avenue, Wuhan, Hubei, China
